INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

	Approved for use through 11/30/2007.
Application Number	10/568,711
Confirmation Number	4660
Filing Date	February 17, 2006
First Named Inventor	Hidenori URATA
Art Unit	1611
Examiner Name	Joseph S. Kudla
Attorney Docket Number	Q93208

	U.S. PATENTS						
Examiner Cite No Patent Number Kind Code ¹ Issue Date Name of Patentee or Where Relevant Passage						Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1					·	

	U.S. PATENT APPLICATION PUBLICATIONS							
Examiner Initials* Cite No Publication Number Kind Code Publication Date Name of Patentee or Applicant of cited Document Where Relevant Passages or Applicant of cited Document Appear						Where Relevant Passages or		
	1							

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	1	1312379	EP	Α	2003-05-21	Takeda Chemical Inudustries Lt		
	2	0132621	wo	Α	2001-05-10	Wakunaga Pharma Co Ltd.		
	3	1192949	EP	А	2002-04-03	Suntory Ltd; Dalichi Suntory Pharma Co Ltd		
	4	1211249	EP	А	2002-06-05	Santen Pharma Co Ltd.		
	5	03018061	wo	Α	2003-03-06	Teijin Ltd		
	6	1249450	EP	А	2002-10-16	Teijin Ltd, Teijin Pharma Ltd		
	7	1097926	EP	Α	2001-05-09	Teijin Ltd		
	8	1099690	EP	Α	2001-05-16	Shionogi & Co		
	9	0936216	EP	Α	1999-08-18	Nippon Kayaku KK		
	10	0940400	EP	А	1999-09-08	Yoshitomi Pharmaceutical Mitsubishi Pharma Corp		
	11	1325920	EP	Α	2003-07-09	Toa Eiyo Ltd		

NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T⁵	
	1	INOUE Y ET AL, Impaired glucose metabolism in human chymase transgenic mouse, Journal of Hypertension, Current Science, Philadelphia, PA, US, vol. 22 no. Suppl. 1, February 1, 2004 page s49, XP009115432		
	2	IZUMI K ET AL, "ACE sogalyaku ni yoru insulin teikosel kaizen no mechanism/ACE INHIBITOR, INSULIN RESISTANCE, ANOIOTENSIN II TYPE 1 RECEPTOR, BRADYKININ BZ RECEPTOR "ANBIUNIP! TONYOBYOKA-ENDOCRINOLOGY AND DIABETOLOGY, KAGAKU HYOROMNS, Tokyo, JP vol. 12, no. 4, April 1, 2001 pas 381-397, YPO02995611.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04.2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3.) for Japanese parted rocuments, the indication of the year of the reging or the Emperor must proceed the serial marker of the patent document, at Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

MODIFIED PTO/SB/08a (05-07)

	NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where publisher. (iv., and/or country where published.	T ⁵			
	3	MASAKI HIDEKAZU ET AL, " Structure-activity relationship of benzo [b] thiophene-2-sulfonamide derivatives as novel human chymase inhibitors". Bioorganic & Medical Chemistry Letters, vol. 13, no. 22, November 17, 2003 pages 4085-4088, XP002523990				
	4	AKAHOSHIF ET AL., "Non-peptidic inhibitors of human chymase. Synthesis structure-activity relationships, and pharmacokinetic profiles of a series of 5-mino-6-xox-1, 6-dhiydropyrimidine-containing triflucromethyl ketones: "Bioorganic & Medicinal Chemistry, February 2, 2001, vol. 9, no. 2, pages 301- 315, XP002523991				
	5	HUANG XIAO R ET AL., "Chymase is upregulated in diabetic nephropathy: Implications for an alternative pathway of angiotension Il-mediated diabetic renal and vascular disease." Journal of The American Society of Nephrology, vol. 14, no. 7, July 2003, pages 1738-1747, XP002524027				
	6	KUEHN L ET AL, "Changes in proteinase/proteinase inhibitor levels in rat skeletal muscle tissue during diabetes and fasting" Biological Chemistry Hoppe-Seyler, Walter DE Gruyter, Berlin, DE, vol. 369, no. suppl, May 1, 1988, pages 299-305, XP009115424				
	7	European Search Report dated June 23, 2009 for EP Application No. 04772291.3-2123				

EXAMINER SIGNATURE				
Examiner Signature	/Kyle Purdy/	Date Considered	10/28/2009	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or IMPEP 901.04. 2. Enter office that Issued the document, by the to-clerifice code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the mign of the Emperor must precede the serial number of the patent document, at Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.